Revisions to Brazil's drug price framework are coming - what's included and what's missing? Our analysts provide th… https://t.co/8s17gnKCXf
IHS examines the global experience with risk sharing agreements in recent conference presentation
Last week I presented, with IHS colleague Sarika Pundit, about the global experience with risk sharing agreements at the CBI Reimbursement and Contracting conference in Philadelphia. Among other things, we examined the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of finance-based agreements. The therapeutic areas most likely to be affected by risk sharing were also reviewed, along with recent regulatory developments that could encourage greater utilisation of risk sharing deals. The analysis was based on the IHS Risk Sharing database and our Payer Partnerships Multi Client study, with additional insights provided from risk sharing coverage in our Same Day Analysis service, Special reports and the IHS International Reference Pricing (IRP) matrix. An abbreviated version of the presentation is available below.
Milena Izmirlieva is the head of the life sciences research team at IHS
Posted 3 March 2015
- Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
- Will IRP upend Czech orphan drug reforms?
- Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
- Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
- Will physicians become more difficult to find in America?
- California's Medicaid pharmacy "carve-out" set to boost state's negotiating power, introduce IRP for drugs
- Trend towards HTA collaboration boosts need for data
- Barriers to market access for innovative medicines increase in the COVID era
Major changes to Czech P&R regulations for orphan and high-cost drugs set to expand access. What role will IRP play… https://t.co/bQcVCG5jut